{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:54:17Z","timestamp":1793976857350,"version":"4.8.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-coi240037-4\"><jats:title>Importance<\/jats:title><jats:p>Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-5\"><jats:title>Objective<\/jats:title><jats:p>To validate graded kidney response criteria and their association with kidney and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-7\"><jats:title>Exposure<\/jats:title><jats:p>Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP \u2264200 mg), very good partial response (kidVGPR, &amp;amp;gt;60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, \u226430% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Cumulative incidence of progression to KRT and OS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-9\"><jats:title>Results<\/jats:title><jats:p>Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL\/min\/1.73m<jats:sup>2<\/jats:sup>, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; <jats:italic>P<\/jats:italic>\u2009=\u2009.002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR\/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR\/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240037-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR\/kidVGPR compared with kidPR\/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.2629","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:49:40Z","timestamp":1722527380000},"page":"1362","source":"Crossref","is-referenced-by-count":41,"title":["Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis"],"prefix":"10.1001","volume":"10","author":[{"given":"Eli","family":"Muchtar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Wisniowski","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"Medical Department V, Amyloidosis Center, University of Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaya","family":"Veelken","sequence":"additional","affiliation":[{"name":"Medical Department V, Amyloidosis Center, University of Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Medical Department V, Amyloidosis Center, University of Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ulloa","sequence":"additional","affiliation":[{"name":"Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Szalat","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dooley","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Petrlik","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Foard","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jullian","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi240037r1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review.","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"coi240037r2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.mayocp.2018.08.006","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing.","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"coi240037r3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"4","key":"coi240037r4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis.","volume":"105","author":"Schulman","year":"2020","journal-title":"Eur J Haematol"},{"issue":"10","key":"coi240037r5","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"coi240037r6","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"4","key":"coi240037r7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"10","key":"coi240037r8","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"coi240037r9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"coi240037r10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician\u2019s choice in relapsed or refractory AL amyloidosis.","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"issue":"28","key":"coi240037r11","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis.","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi240037r12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis.","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240037r13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis.","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"coi240037r14","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"23","key":"coi240037r15","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020.","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"7","key":"coi240037r16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis.","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi240037r17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"coi240037r18","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"coi240037r19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.15832","article-title":"Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.","volume":"185","author":"Sidana","year":"2019","journal-title":"Br J Haematol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2821927\/jamaoncology_muchtar_2024_oi_240037_1728488943.25876.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:19:11Z","timestamp":1729178351000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2821927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.2629","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}